{"id":829465,"date":"2025-03-25T08:54:03","date_gmt":"2025-03-25T12:54:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/"},"modified":"2025-03-25T08:54:03","modified_gmt":"2025-03-25T12:54:03","slug":"maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/","title":{"rendered":"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth11 { width: 11% }\n.bwwidth88 { width: 88% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)<\/b><\/li>\n<\/ul>\n<p>\n\u00a0\n<\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>MAIA Biotechnology, Inc., (NYSE American: MAIA)<\/b> (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO).\n<\/p>\n<p>\n\u201cWe are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,\u201d said Vlad Vitoc, M.D., CEO of MAIA. \u201cOur poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive immune response biomarker for THIO sequenced with a checkpoint inhibitor. Predictive biomarkers can further illuminate THIO\u2019s unique mechanisms of action which have shown exceptional efficacy in our Phase 2 clinical trial.\u201d\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Presentation details:<\/b><\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTitle:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPhase 2 Study of Telomere-Targeting Agent THIO Sequenced by Cemiplimab in Immune Checkpoint Inhibitor-Resistant Advanced NSCLC: Interleukin-6 as a Potential Predictive Biomarker\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAbstract number:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n997\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDate:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMarch 28, 2025\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTime:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n12:00 p.m. CET\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPresenter:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTomasz Jankowski, M.D., Ph.D. \u2013 Lead investigator for THIO-101 Phase 2 clinical trial\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth11\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster access:\n<\/p>\n<\/td>\n<td class=\"bwwidth1\" rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwwidth88\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMAIA\u2019s poster will be available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fmaiabiotech.com%2Fpublications&amp;esheet=54228033&amp;newsitemid=20250325817866&amp;lan=en-US&amp;anchor=maiabiotech.com%2Fpublications&amp;index=1&amp;md5=b64e967d34a53d9bf35e4b14bd62bbcd\">maiabiotech.com\/publications<\/a> on March 28, 2025\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.\n<\/p>\n<p><b>About Ateganosine<\/b><\/p>\n<p>\nAteganosine (THIO, 6-thio-dG or 6-thio-2\u2019-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2\u2019-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS\/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type\u2013specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.\n<\/p>\n<p><b>About MAIA Biotechnology, Inc.<\/b><\/p>\n<p>\nMAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maiabiotech.com&amp;esheet=54228033&amp;newsitemid=20250325817866&amp;lan=en-US&amp;anchor=www.maiabiotech.com&amp;index=2&amp;md5=1a51d19a8487d320fc1b916ef2c5cd55\">www.maiabiotech.com<\/a>.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nMAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, \u201cMAIA,\u201d \u201cCompany,\u201d \u201cwe,\u201d \u201cour,\u201d and \u201cus\u201d refers to MAIA Biotechnology, Inc. and its subsidiaries.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250325817866\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250325817866\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact<br \/>\n<\/b><br \/>+1 (872) 270-3518<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@maiabiotech.com\">ir@maiabiotech.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America France Illinois<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250325817866\/en\/1861426\/3\/MAIA_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025 Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) \u00a0 CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). \u201cWe are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,\u201d said Vlad Vitoc, M.D., CEO of MAIA. \u201cOur poster &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829465","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIA Biotechnology Announces Poster Presentation at ESMO&#039;s European Lung Cancer Congress 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Biotechnology Announces Poster Presentation at ESMO&#039;s European Lung Cancer Congress 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025 Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) \u00a0 CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). \u201cWe are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,\u201d said Vlad Vitoc, M.D., CEO of MAIA. \u201cOur poster &hellip; Continue reading &quot;MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:54:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025\",\"datePublished\":\"2025-03-25T12:54:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/\"},\"wordCount\":908,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/\",\"name\":\"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-25T12:54:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Market Newsdesk","og_description":"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025 Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) \u00a0 CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). \u201cWe are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,\u201d said Vlad Vitoc, M.D., CEO of MAIA. \u201cOur poster &hellip; Continue reading \"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:54:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025","datePublished":"2025-03-25T12:54:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/"},"wordCount":908,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/","name":"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-25T12:54:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250325817866r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-announces-poster-presentation-at-esmos-european-lung-cancer-congress-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MAIA Biotechnology Announces Poster Presentation at ESMO&#8217;s European Lung Cancer Congress 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829465"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829465\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}